|Dr. John D. Mendlein Ph.D., J.D.||CEO & Director||703.66k||N/A||57|
|Dr. Paul R. Schimmel Ph.D.||Founder & Director||40k||N/A||76|
|Dr. Sanuj K. Ravindran M.D.||Chief Bus. Officer||565.22k||N/A||45|
|Dr. Sanjay S. Shukla M.D., M.S.||Chief Medical Officer||483.58k||N/A||45|
|Xiang-Lei Yang Ph.D.||Founder||N/A||N/A||N/A|
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 8; Compensation: 8.